DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers
- PMID: 24727449
- DOI: 10.1016/j.bbrc.2014.03.144
DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers
Abstract
DDX4 (DEAD box polypeptide 4), characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), is an RNA helicase which is implicated in various cellular processes involving the alteration of RNA secondary structure, such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. DDX4 is known to be a germ cell-specific protein and is used as a sorting marker of germline stem cells for the production of oocytes. A recent report about DDX4 in ovarian cancer showed that DDX4 is overexpressed in epithelial ovarian cancer and disrupts a DNA damage-induced G2 checkpoint. We investigated the relationship between DDX4 and ovarian cancer stem cells by analyzing the expression patterns of DDX4 and the cancer stem cell marker CD133 in ovarian cancers via tissue microarray. Both DDX4 and CD133 were significantly increased in ovarian cancer compared to benign tumors, and showed similar patterns of expression. In addition, DDX4 and CD133 were mostly colocalized in various types of ovarian cancer tissues. Furthermore, almost all CD133 positive ovarian cancer cells also express DDX4 whereas CD133-negative cells did not possess DDX4, suggesting a strong possibility that DDX4 plays an important role in cancer stem cells, and/or can be used as an ovarian cancer stem cell marker.
Keywords: CD133; Cancer stem cells; DDX4; Ovarian cancer.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.Neoplasma. 2012;59(3):310-5. doi: 10.4149/neo_2012_040. Neoplasma. 2012. PMID: 22296500
-
DEAD-Box Helicase 4 (Ddx4)+ Stem Cells Sustain Tumor Progression in Non-Serous Ovarian Cancers.Int J Mol Sci. 2020 Aug 24;21(17):6096. doi: 10.3390/ijms21176096. Int J Mol Sci. 2020. PMID: 32847044 Free PMC article.
-
Expression patterns of Thymosin β4 and cancer stem cell marker CD133 in ovarian cancers.Pathol Oncol Res. 2013 Apr;19(2):237-45. doi: 10.1007/s12253-012-9574-0. Epub 2012 Oct 10. Pathol Oncol Res. 2013. PMID: 23055022
-
CD133 as a marker for cancer stem cells: progresses and concerns.Stem Cells Dev. 2009 Oct;18(8):1127-34. doi: 10.1089/scd.2008.0338. Stem Cells Dev. 2009. PMID: 19409053 Review.
-
CD133: molecule of the moment.J Pathol. 2008 Jan;214(1):3-9. doi: 10.1002/path.2283. J Pathol. 2008. PMID: 18067118 Review.
Cited by
-
Ovarian Cancer Stem Cells: Unraveling a Germline Connection.Stem Cells Dev. 2017 Dec 15;26(24):1781-1803. doi: 10.1089/scd.2017.0153. Epub 2017 Nov 28. Stem Cells Dev. 2017. PMID: 29078734 Free PMC article.
-
A Comprehensive Molecular and Clinical Analysis of the piRNA Pathway Genes in Ovarian Cancer.Cancers (Basel). 2020 Dec 22;13(1):4. doi: 10.3390/cancers13010004. Cancers (Basel). 2020. PMID: 33374923 Free PMC article.
-
Chemotherapy targeting cancer stem cells.Am J Cancer Res. 2015 Feb 15;5(3):880-93. eCollection 2015. Am J Cancer Res. 2015. PMID: 26045975 Free PMC article. Review.
-
Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis.Int J Clin Exp Med. 2015 Mar 15;8(3):3080-8. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26064196 Free PMC article. Review.
-
An unregulated regulator: Vasa expression in the development of somatic cells and in tumorigenesis.Dev Biol. 2016 Jul 1;415(1):24-32. doi: 10.1016/j.ydbio.2016.05.012. Epub 2016 May 11. Dev Biol. 2016. PMID: 27179696 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials